Ph20 polypeptide variants, formulations and uses thereof
AssigneeHalozyme, Inc.
InventorsGe WEI, H. Michael SHEPARD, Qiping ZHAO, Robert James CONNOR
Life of this patent
Estimating the term…
Abstract
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Claims20
1-23. (canceled)
A nucleic acid encoding the modified PH20 polypeptide, the modified PH20 polypeptide comprising an amino acid sequence, wherein:
- (a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in an amino acid sequence selected from the group consisting of SEQ ID NO:
- 35 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence selected from the group consisting of SEQ ID NO:
- 35 to maximize identical residues, and wherein terminal gaps are treated as non-identical;
- and
- (b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 309 with reference to amino acid positions set forth in SEQ ID NO:
- 3;
- and
- (c) the modification at position 309 is a replacement selected from among E, G, H, L, M, N, Q, R, S, and T.
A method for administering a therapeutically active agent, comprising providing a pharmaceutical composition, and parenterally administering the pharmaceutical composition,
- wherein the pharmaceutical composition comprises
- a modified PH20 polypeptide comprising an amino acid sequence, wherein:
- (a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in an amino acid sequence selected from the group consisting of SEQ ID NO:
- 35 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence selected from the group consisting of SEQ ID NO:
- 35 to maximize identical residues, and wherein terminal gaps are treated as non-identical, and
- (b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 309 with reference to amino acid positions set forth in SEQ ID NO:
- 3, and
- (c) the modification at position 309 is a replacement selected from among E, G, H, L, M, N, Q, R, S, and T;
- and
- the therapeutically active agent.
A method for treating cancer, comprising administering a pharmaceutical composition, wherein the pharmaceutical composition comprises a modified PH20 polypeptide comprising an amino acid sequence, wherein:
- (a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in an amino acid sequence selected from the group consisting of SEQ ID NO:
- 35 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence selected from the group consisting of SEQ ID NO:
- 35 to maximize identical residues, and wherein terminal gaps are treated as non-identical;
- and
- (b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 309 with reference to amino acid positions set forth in SEQ ID NO:
- 3;
- and
- (c) the modification at position 309 is a replacement selected from among E, G, H, L, M, N, Q, R, S, and T.
Dependencies are inferred from the claim text.